Bladder Cancer Treatment Is Advancing Faster Than Answers on Sequencing and Toxicity Management

Bladder cancer treatment has changed rapidly with the introduction of antibody-drug conjugates, immunotherapies, intravesical therapies, and biomarker-guided approaches across multiple disease settings. These advances have improved outcomes and expanded bladder-preserving options, but they have also created questions about treatment sequencing, patient selection, adverse-event management, and coordination between medical oncology and urology.